Preapproval inspections to focus on data integrity and fraud
This article was originally published in The Gold Sheet
Executive Summary
CDER official Rick Friedman asserted that FDA's action was prompted by recent criminal investigations, including the Department of Justice's prosecution in March 2007 of a former vice-president in charge of quality control and three supervisory chemists who pleaded guilty to conspiracy involving the rampant falsification of records. "We have found other deficiencies including acceptance of failed runs," reported Friedman at a June 23 conference in New Brunswick N.J. sponsored by Pharma Conference and the University of Rhode Island College of Pharmacy. "This has shown that many of these investigations are undermining the safety and efficacy of these products." Other examples of fraud include biased manipulation of study data, alternating weights of samples and changing weights of standardized samples. To combat this problem, FDA is "reinvigorating" specialized training of investigational staff to address data integrity, manipulation and fraud issues. Friedman recommended that manufacturers "train employees in proper data handling and reporting. Employees need to know how to identify suspect data in clinical trials and how to identity suspect GMP data. Everyone in the organization needs to be responsible for data integrity
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.